repro med sys - KRMD

KRMD

Close Chg Chg %
4.27 0.05 1.17%

Closed Market

4.32

+0.05 (1.17%)

Volume: 53.64K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Company Overview: repro med sys - KRMD

KRMD Key Data

Open

$4.19

Day Range

4.15 - 4.33

52 Week Range

1.87 - 6.61

Market Cap

$198.00M

Shares Outstanding

46.37M

Public Float

43.36M

Beta

0.54

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.06

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

153.77K

 

KRMD Performance

1 Week
 
2.37%
 
1 Month
 
-5.05%
 
3 Months
 
-22.99%
 
1 Year
 
89.47%
 
5 Years
 
20.67%
 

KRMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About repro med sys - KRMD

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

KRMD At a Glance

KORU Medical Systems, Inc.
100 Corporate Drive
Mahwah, New Jersey 07430
Phone 1-845-469-2042 Revenue 41.13M
Industry Medical Specialties Net Income -2,637,926.00
Sector Health Technology 2025 Sales Growth 22.234%
Fiscal Year-end 12 / 2026 Employees 73
View SEC Filings

KRMD Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 6.525
Price to Book Ratio 15.803
Price to Cash Flow Ratio 580.34
Enterprise Value to EBITDA -121.637
Enterprise Value to Sales 6.394
Total Debt to Enterprise Value 0.013

KRMD Efficiency

Revenue/Employee 563,388.575
Income Per Employee -36,135.973
Receivables Turnover 6.298
Total Asset Turnover 1.418

KRMD Liquidity

Current Ratio 2.439
Quick Ratio 1.99
Cash Ratio 1.083

KRMD Profitability

Gross Margin 60.285
Operating Margin -7.227
Pretax Margin -6.361
Net Margin -6.414
Return on Assets -9.094
Return on Equity -15.581
Return on Total Capital -12.84
Return on Invested Capital -13.182

KRMD Capital Structure

Total Debt to Total Equity 20.508
Total Debt to Total Capital 17.018
Total Debt to Total Assets 11.827
Long-Term Debt to Equity 17.35
Long-Term Debt to Total Capital 14.398
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Repro Med Sys - KRMD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
27.90M 28.52M 33.65M 41.13M
Sales Growth
+18.76% +2.23% +17.98% +22.23%
Cost of Goods Sold (COGS) incl D&A
13.11M 12.68M 13.20M 16.33M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
587.14K 870.39K 888.47K 810.50K
Depreciation
524.99K 805.92K 820.28K 741.09K
Amortization of Intangibles
62.14K 64.47K 68.20K 69.41K
COGS Growth
+28.78% -3.31% +4.13% +23.71%
Gross Income
14.78M 15.84M 20.44M 24.79M
Gross Income Growth
+11.09% +7.14% +29.08% +21.28%
Gross Profit Margin
+52.99% +55.54% +60.76% +60.28%
2022 2023 2024 2025 5-year trend
SG&A Expense
25.56M 26.11M 26.89M 27.77M
Research & Development
4.96M 5.74M 5.26M 4.39M
Other SG&A
20.61M 20.37M 21.63M 23.38M
SGA Growth
+25.70% +2.13% +2.99% +3.26%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(10.78M) (10.27M) (6.45M) (2.97M)
Non Operating Income/Expense
105.72K 496.40K 382.49K 356.40K
Non-Operating Interest Income
145.59K 561.33K 444.64K 293.40K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(10.68M) (9.77M) (6.06M) (2.62M)
Pretax Income Growth
-67.73% +8.45% +37.96% +56.86%
Pretax Margin
-38.27% -34.27% -18.02% -6.36%
Income Tax
(2.01M) 3.97M 2.89K 21.89K
Income Tax - Current - Domestic
- 6.00M 2.89K 21.89K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - (2.01M) (2.04M)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(8.66M) (13.74M) (6.07M) (2.64M)
Minority Interest Expense
- - - -
-
Net Income
(8.66M) (13.74M) (6.07M) (2.64M)
Net Income Growth
-89.82% -58.65% +55.85% +56.52%
Net Margin Growth
-31.05% -48.18% -18.03% -6.41%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(8.66M) (13.74M) (6.07M) (2.64M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(8.66M) (13.74M) (6.07M) (2.64M)
EPS (Basic)
-0.1925 -0.3013 -0.1325 -0.0571
EPS (Basic) Growth
-87.26% -56.52% +56.02% +56.91%
Basic Shares Outstanding
45.00M 45.60M 45.80M 46.19M
EPS (Diluted)
-0.1925 -0.3013 -0.1325 -0.0571
EPS (Diluted) Growth
-87.26% -56.52% +56.02% +56.91%
Diluted Shares Outstanding
45.00M 45.60M 45.80M 46.19M
EBITDA
(10.19M) (9.40M) (5.56M) (2.16M)
EBITDA Growth
-55.24% +7.79% +40.87% +61.10%
EBITDA Margin
-36.54% -32.96% -16.52% -5.26%

Snapshot

Average Recommendation BUY Average Target Price 6.80
Number of Ratings 5 Current Quarters Estimate -0.012
FY Report Date 06 / 2026 Current Year's Estimate -0.034
Last Quarter’s Earnings -0.02 Median PE on CY Estimate N/A
Year Ago Earnings -0.06 Next Fiscal Year Estimate 0.032
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.01 -0.01 -0.03 0.03
High Estimates 0.00 0.00 -0.02 0.06
Low Estimate -0.02 -0.01 -0.05 -0.01
Coefficient of Variance -69.73 -55.90 -39.46 92.18

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Repro Med Sys - KRMD

Date Name Shares Transaction Value
Jan 16, 2026 Eric Schiller Chief Technology Officer 76,426 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 16, 2026 Eric Schiller Chief Technology Officer 232,297 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Repro Med Sys in the News